ADOMAH OPONG: Open Payments
NPI 1518215151 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$857 in 26 payments from 11 companies in 2025. Trend: 2023 $745 · 2024 $715 · 2025 $857
Food & beverage: $857
| Company | Payments | Amount |
|---|---|---|
| Genentech, Inc. | 2 | $268 |
| Novartis Pharmaceuticals Corporation | 9 | $217 |
| Alexion Pharmaceuticals, Inc. | 3 | $76 |
| Azurity Pharmaceuticals, Inc. | 2 | $61 |
| Astellas Pharma US Inc | 2 | $56 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Celgene Corporation | 2 | $37 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Janssen Biotech, Inc. | 1 | $21 |
Products named: Venclexta, Fabhalta, ULTOMIRIS, SCEMBLIX, DANZITEN, Cresemba, Vanflyta, REBLOZYL.
Industry payments across NY — which companies pay providers there.
